C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

Slides:

Advertisements

Similar presentations

P-4E-BP1/4E-BP1P-p70 S6K/p70 S6K ND cleaved PARP/PARPLC3II/LC3I Supplementary Figure 1 Relative levels A BC P-Akt/Akt.

Advertisements

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group.

Supplemental Table 1 Source and authentication of cell lines.

Differential drug responses of circulating tumor cells within patient blood Andrew D. Hughes, Jocelyn R. Marshall, Eric Keller, John D. Powderly, Bryan.

Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure (µM) Penetratin control % of control (µM)

Quantitative Single-Cell Approaches to Stem Cell Research Martin Etzrodt, Max Endele, Timm Schroeder Cell Stem Cell Volume 15, Issue 5, Pages (November.

The reading is 7.38 mm. The reading is 7.72 mm.

Supplementary information Figure S1 Parental Mock ANXA1-V5 GAPDH MCF7-EV MCF7-V5 4 5 ANXA1 ANXA1-V5 Tubulin MCF7-parental MCF7-EV MCF7-V A B C ANXA1.

Shimura Supplemental Figure 1

Supplementary Figure S1 a

Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM

A new opportunity for nanomedicines: Micellar cytochrome P450 inhibitors to improve drug efficacy in a cancer therapy model Marion Paolini, Laurence.

Figure 3. Synergistic effects of the combination of trabectedin and olaparib on poly(ADP-ribosyl)ation and DNA damage in four different breast cancer cell.

Neal et al.Supplementary Figure S1

Supplementary Figure 1 Lapatinib nM mM pEGFR MDA-MB231 EGFR pEGFR

Supplementary Figure S1.

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

A Untreated mM maphos, 48h 20 mM maphos, 48h 50 mM maphos, 48hh B

Online Gifts Buy for wishes happy mother's day to yours choice and with happy gifts find here:

a b c d Supplemental Figure S x108 IFU 2x108 IFU 28 28

T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC

Supplemental Information

1A 1B Supplementary Figure 1. Parp HT29 C-Parp Gapdh LoVo

A B C D E F Supplementary Fig. 1. Gating strategy for CD44+CD133+CD24+ B16 tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells.

A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were.

Days after cell inoculation Days after cell inoculation

Days after cell inoculation Days after cell inoculation

Supplementary figure 1.

BV6 increases tumor burden in bone.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Validation of St6GalNAc2 as a metastasis suppressor gene.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.

SKAP55‐deficient mice enhance DC‐based vaccine for prevention of tumors in vivo AWT and SKAP55 KO C57BL/6 mice were s.c. immunized on day −14 and day −7.

Supplementary figure1. CK7 CK20 CDX2 DPEP1 Cut off value: 85%

A B Supplementary figure S5 ** ** ** ** ** **

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Volume 7, Issue 2, Pages (February 2003)

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

Volume 133, Issue 6, Pages (June 2008)

Supp. Figure 1 MM-302 trastuzumab Vessels Hoechst Merge.

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Supplementary Figure S1

A B C D E F Supplementary Fig. 3. Gating strategy for ES2 ALDHhi tumor initiating cells (TIC). Cells were treated with the specific aldehyde dehydrogenase.

The Chemical Biology of Human Vitamins

Supplementary figure 1 A B Water (Control) Pre-alcohol Post-alcohol

Antitumor immunity caused by DS-8201a.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

coTCRcys-transduced T cells control tumor growth in vivo.

Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but not OVA Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Matriptase-2 inhibited breast tumor development in vivo.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

Induction of a tumor-specific immune response following radiofrequency ablation (RFA). Induction of a tumor-specific immune response following radiofrequency.

Long circulation time, passive tumor targeting, and photothermal heating of passively targeted gold NR antennas in tumors. Long circulation time, passive.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.

VC KX-01 Total Src p-Y416 Src Supplementary Figure S1. KX-01 at low dose inhibited phosphorylation of Src in MDA-MB-231 xenografts.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Intraperitoneal or intratumoral injection of 6-thio-dG or 6-thioguanine. Intraperitoneal or intratumoral injection of 6-thio-dG or 6-thioguanine. A, 2.

Effect of dietary feeding of silibinin on DU145 tumor xenograft growth in athymic male nude mice. Effect of dietary feeding of silibinin on DU145 tumor.

Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv) localization in tumor-bearing mice and BsAb half-life in mouse blood. Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv)

Fig. 1 RNA methyltransferase METTL14 and demethylase ALKBH5 promote growth and invasion of breast cancer cells. RNA methyltransferase METTL14 and demethylase.

Presentation transcript:

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc. HER2 PD-L1 PD-L2 -14d X-ray, hPBMC iv. 7d Tumor cells sc. -15d 0d 14d BsAb (Study scheme) 10 1 2 3 4 20 40 60 80 100 % of Max 10 2 3 4 5 20 40 60 80 100 % of Max 10 2 3 4 5 20 40 60 80 100 % of Max MDA-MB-468 10 1 2 3 4 20 40 60 80 100 10 1 2 3 4 20 40 60 80 100 % of Max 10 1 2 3 4 20 40 60 80 100 % of Max HCC1954 10 1 2 3 4 20 40 60 80 100 10 1 2 3 4 20 40 60 80 100 % of Max 10 1 2 3 4 20 40 60 80 100 % of Max HCC1569 HCC1954 Tumor volume (mm3) * B Days after initial injection HCC1569 Tumor volume (mm3) * * * Days after initial injection